​

Stoke Therapeutics Ownership | Who Owns Stoke Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Stoke Therapeutics Ownership Summary

Stoke Therapeutics is owned by 121.55% institutional investors, 3.66% insiders. Blackrock is the largest institutional shareholder, holding 11.70% of STOK shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.03% of its assets in Stoke Therapeutics shares.

STOK Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockStoke Therapeutics121.55%3.66%-25.21%
SectorHealthcare Stocks 244.59%12.11%-156.70%
IndustryBiotech Stocks 379.61%11.70%-291.31%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock5.41M11.70%$73.08M
Blackrock funding, inc. /de5.88M9.32%$192.31M
Rtw investments, lp5.62M8.92%$184.00M
Fmr5.31M8.43%$173.84M
Cowen and company3.37M7.28%$45.47M
Lynx1 capital management lp4.04M6.40%$132.14M
Redmile group3.95M6.26%$129.11M
Wellington management group llp3.52M5.58%$115.15M
Morgan stanley3.45M5.48%$112.98M
Vanguard group3.15M5.37%$99.96M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Skorpios trust2.26M99.68%$53.02M
Lynx1 capital management lp4.04M26.03%$132.14M
Redmile group3.95M8.67%$129.11M
Birchview capital, lp178.11K2.73%$5.83M
Bvf inc/il2.55M2.13%$83.36M
Opaleye management700.00K2.07%$22.90M
Troluce capital advisors496.42K1.67%$16.24M
Checkpoint capital212.05K1.67%$4.98M
Rtw investments, lp5.62M1.57%$184.00M
Bioimpact capital723.31K1.44%$23.67M

Top Buyers

HolderShares% AssetsChange
T. rowe price investment management2.42M0.05%2.16M
Blackrock5.41M0.00%1.55M
Price t rowe associates inc /md/2.66M0.01%727.57K
Ecor1 capital735.00K1.17%635.00K
State street2.85M0.00%575.73K

Top Sellers

HolderShares% AssetsChange
Janus henderson group18.90K0.00%-1.43M
Healthcare of ontario pension plan trust fund---1.39M
Point72 asset management---1.22M
Logos global management lp---1.05M
Skorpios trust2.26M99.68%-1.00M

New Positions

HolderShares% AssetsChangeValue
Sixth street partners management company467.01K0.00%467.01K$15.28M
Norges bank163.20K0.00%163.20K$5.34M
Exoduspoint capital management, lp129.66K0.03%129.66K$4.24M
Jump financial104.35K0.03%104.35K$3.41M
Trexquant investment lp73.47K0.01%73.47K$2.40M

Sold Out

HolderChange
Mai capital management-3.00
Twin peaks wealth advisors-3.00
Nelson, van denburg & campbell wealth management group-5.00
Parallel advisors-13.00
Mid-american wealth advisory group-17.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2026201-1.47%76,652,9657.80%1210.84%110-9.09%577.55%
Mar 31, 20262003.63%68,902,3742.86%1160.89%11613.73%54-8.47%
Dec 31, 202582-47.44%14,262,199-78.93%240.18%43-52.22%21-46.15%
Sep 30, 202564-49.61%15,482,785-74.37%260.25%38-47.95%16-44.83%
Jun 30, 20251334.72%65,529,80716.03%1121.18%732.82%3322.22%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.89M3.03%152.84K
Vanguard Morn Total Stk Mkt Idx Investor1.89M3.03%152.84K
Vanguard US Total Market Shares ETF1.61M2.97%-
Vanguard Health Care Inv1.83M2.94%177.44K
Vanguard MStar Total Stk Mkt Idx Invest1.90M2.94%9.61K
State Street® SPDR® S&P® Biotech ETF1.55M2.40%3.56K
Fidelity Select Biotechnology1.46M2.35%169.49K
iShares Russell 2000 ETF1.38M2.14%-24.58K
BGF World Healthscience A2 USD851.11K1.56%-
Polar Capital Biotech S Inc789.60K1.27%-

Recent Insider Transactions

DateNameRoleActivityValue
Sep 01, 2026Ticho Barry CHIEF MEDICAL OFFICERSell$120.37K
Sep 01, 2026Ticho Barry CHIEF MEDICAL OFFICERSell$49.69K
Aug 18, 2026Ticho Barry CHIEF MEDICAL OFFICERSell$7.86K
Aug 18, 2026Ticho Barry CHIEF MEDICAL OFFICERSell$144.83K
Aug 18, 2026Kaye Edward M. MD-Sell$381.85K

Insider Transactions Trends

DateBuySell
2026 Q3-12
2026 Q2-4
2026 Q1-27
2025 Q4-42
2025 Q3-13

STOK Ownership FAQ

Who Owns Stoke Therapeutics?

Stoke Therapeutics shareholders are primarily institutional investors at 121.55%, followed by 3.66% insiders and -25.21% retail investors. The average institutional ownership in Stoke Therapeutics's industry, Biotech Stocks , is 379.61%, which Stoke Therapeutics falls below.

Who owns the most shares of Stoke Therapeutics?

Stoke Therapeutics’s largest shareholders are Blackrock (5.41M shares, 11.70%), Blackrock funding, inc. /de (5.88M shares, 9.32%), and Rtw investments, lp (5.62M shares, 8.92%). Together, they hold 29.93% of Stoke Therapeutics’s total shares outstanding.

Does Blackrock own Stoke Therapeutics?

Yes, BlackRock owns 11.70% of Stoke Therapeutics, totaling 5.41M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 73.08M$. In the last quarter, BlackRock increased its holdings by 1.55M shares, a 40.19% change.

Who is Stoke Therapeutics’s biggest shareholder by percentage of total assets invested?

Skorpios trust is Stoke Therapeutics’s biggest shareholder by percentage of total assets invested, with 99.68% of its assets in 2.26M Stoke Therapeutics shares, valued at 53.02M$.

Who is the top mutual fund holder of Stoke Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Stoke Therapeutics shares, with 3.03% of its total shares outstanding invested in 1.89M Stoke Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools